Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AARD NASDAQ:EPRX NASDAQ:IMMX NASDAQ:KMDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$5.65-4.0%$5.45$3.35▼$17.94$123.26M5.11249,312 shs85,614 shsEPRXEupraxia Pharmaceuticals$7.43-2.0%$7.39$3.67▼$9.32$449.12M1.19210,948 shs89,228 shsIMMXImmix Biopharma$9.73-5.8%$9.32$1.87▼$11.61$515.28M0.12832,460 shs406,434 shsKMDAKamada$8.26-0.2%$8.52$6.50▼$9.35$474.99M0.8667,969 shs41,820 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics+7.68%+13.05%+42.62%-47.83%-43.64%EPRXEupraxia Pharmaceuticals+4.26%+3.27%+6.76%-10.40%+86.70%IMMXImmix Biopharma+7.95%+19.58%+20.14%+73.45%+429.23%KMDAKamada+0.85%+2.10%0.00%+3.24%+24.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$5.65-4.0%$5.45$3.35▼$17.94$123.26M5.11249,312 shs85,614 shsEPRXEupraxia Pharmaceuticals$7.43-2.0%$7.39$3.67▼$9.32$449.12M1.19210,948 shs89,228 shsIMMXImmix Biopharma$9.73-5.8%$9.32$1.87▼$11.61$515.28M0.12832,460 shs406,434 shsKMDAKamada$8.26-0.2%$8.52$6.50▼$9.35$474.99M0.8667,969 shs41,820 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics+7.68%+13.05%+42.62%-47.83%-43.64%EPRXEupraxia Pharmaceuticals+4.26%+3.27%+6.76%-10.40%+86.70%IMMXImmix Biopharma+7.95%+19.58%+20.14%+73.45%+429.23%KMDAKamada+0.85%+2.10%0.00%+3.24%+24.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAARDAardvark Therapeutics 2.62Moderate Buy$22.60299.86% UpsideEPRXEupraxia Pharmaceuticals 2.75Moderate Buy$15.00102.02% UpsideIMMXImmix Biopharma 2.50Moderate Buy$18.2587.64% UpsideKMDAKamada 2.75Moderate Buy$13.0057.38% UpsideCurrent Analyst Ratings BreakdownLatest AARD, IMMX, EPRX, and KMDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026EPRXEupraxia Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.004/29/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/22/2026EPRXEupraxia Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.004/21/2026EPRXEupraxia Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026IMMXImmix Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/30/2026IMMXImmix Biopharma MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$14.00 ➝ $15.003/27/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026IMMXImmix Biopharma Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$23.003/27/2026IMMXImmix Biopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$12.00 ➝ $15.003/25/2026IMMXImmix Biopharma Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$20.003/24/2026AARDAardvark Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.00(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAARDAardvark TherapeuticsN/AN/AN/AN/A$4.90 per shareN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/A$1.41 per shareN/AIMMXImmix BiopharmaN/AN/AN/AN/A$1.77 per shareN/AKMDAKamada$180.46M2.63$0.61 per share13.44$4.68 per share1.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAARDAardvark Therapeutics-$57.59M-$2.93N/AN/AN/AN/A-44.59%-41.51%N/AEPRXEupraxia Pharmaceuticals-$38.58M-$1.03N/AN/AN/AN/A-167.68%-66.72%N/AIMMXImmix Biopharma-$29.44M-$0.89N/AN/AN/AN/A-101.25%-73.39%5/14/2026 (Estimated)KMDAKamada$20.20M$0.3523.6014.000.6311.19%7.72%5.39%5/13/2026 (Estimated)Latest AARD, IMMX, EPRX, and KMDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026Q1 2026IMMXImmix Biopharma-$0.2084N/AN/AN/AN/AN/A5/14/2026Q1 2026IMMXImmix Biopharma-$0.1450N/AN/AN/AN/AN/A5/13/2026Q1 2026KMDAKamada$0.12N/AN/AN/A$46.72 millionN/A5/7/2026Q1 2026AARDAardvark TherapeuticsN/A-$0.99N/A-$0.99N/AN/A3/25/2026Q4 2025IMMXImmix Biopharma-$0.16-$0.28-$0.12-$0.28N/AN/A3/23/2026Q4 2025AARDAardvark Therapeutics-$0.81-$0.81N/A-$0.81N/AN/A3/19/2026Q4 2025EPRXEupraxia Pharmaceuticals-$0.16-$0.37-$0.21-$0.37N/AN/A3/11/2026Q4 2025KMDAKamada$0.09$0.06-$0.03$0.06$145.07 million$44.68 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAARDAardvark TherapeuticsN/AN/AN/AN/AN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AIMMXImmix BiopharmaN/AN/AN/AN/AN/AKMDAKamada$0.182.18%N/A51.43%N/ALatest AARD, IMMX, EPRX, and KMDA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/11/2026KMDAKamadaannual$0.253.05%3/23/20263/23/20264/7/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAARDAardvark TherapeuticsN/A10.6110.61EPRXEupraxia PharmaceuticalsN/A15.1215.12IMMXImmix BiopharmaN/A10.0110.01KMDAKamadaN/A4.072.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAARDAardvark TherapeuticsN/AEPRXEupraxia PharmaceuticalsN/AIMMXImmix Biopharma11.26%KMDAKamada20.38%Insider OwnershipCompanyInsider OwnershipAARDAardvark TherapeuticsN/AEPRXEupraxia PharmaceuticalsN/AIMMXImmix Biopharma30.30%KMDAKamada36.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAARDAardvark Therapeutics1821.82 millionN/AN/AEPRXEupraxia Pharmaceuticals2960.43 millionN/AN/AIMMXImmix Biopharma953.01 million36.95 millionOptionableKMDAKamada36057.51 million36.75 millionOptionableAARD, IMMX, EPRX, and KMDA HeadlinesRecent News About These CompaniesKamada to Report First-Quarter 2026 Results on May 13May 6 at 7:30 AM | tipranks.comKamada (KMDA) Expected to Announce Quarterly Earnings on WednesdayMay 6 at 7:21 AM | marketbeat.comKamada to Announce First Quarter 2026 Financial Results on May 13, 2026May 6 at 7:00 AM | globenewswire.comContrasting Spyre Therapeutics (NASDAQ:SYRE) and Kamada (NASDAQ:KMDA)May 4 at 3:46 AM | americanbankingnews.comKamada Ltd. (NASDAQ:KMDA) Short Interest UpdateApril 28, 2026 | marketbeat.comSidoti Predicts Kamada's Q1 Earnings (NASDAQ:KMDA)April 20, 2026 | marketbeat.comDavid Tsur Takes A Bullish Stance, Acquiring $113K Worth Of Kamada Stock OptionsApril 10, 2026 | benzinga.comEran Nir Sees Potential Growth And Acquires $178K In Kamada Stock OptionsApril 10, 2026 | benzinga.comKamada Ltd Earnings Call Signals Confident Growth PathApril 2, 2026 | tipranks.comKamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to ShareholdersMarch 31, 2026 | markets.businessinsider.comKamada Details Israeli Withholding Terms for April 7 Cash DividendMarch 31, 2026 | tipranks.comKamada: From Buy To Hold After 22.4% Surge (Rating Downgrade)March 30, 2026 | seekingalpha.comKamada Announces FDA Approval of its Plasma Collection Center in San Antonio, TexasMarch 26, 2026 | globenewswire.comKamada's Pipeline And Biosimilars Set Stage For Future Earnings ExpansionMarch 12, 2026 | seekingalpha.comKamada Ltd. (KMDA) Q4 FY2025 earnings call transcriptMarch 12, 2026 | finance.yahoo.comKamada Ltd’s Dependence on Investigator-Initiated Trials Poses Data Integrity and IP Risks to Its Long-Term GrowthMarch 12, 2026 | tipranks.comKamada (KMDA) Q4 Earnings and Revenues Miss EstimatesMarch 11, 2026 | finance.yahoo.comKamada Ltd (KMDA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic OutlookMarch 11, 2026 | finance.yahoo.comKamada Ltd. (KMDA) Q4 2025 Earnings Call TranscriptMarch 11, 2026 | seekingalpha.comKamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable GrowthMarch 11, 2026 | globenewswire.comKamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend PolicyMarch 11, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAARD, IMMX, EPRX, and KMDA Company DescriptionsAardvark Therapeutics NASDAQ:AARD$5.65 -0.24 (-4.04%) As of 03:17 PM Eastern This is a fair market value price provided by Massive. Learn more.Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.Eupraxia Pharmaceuticals NASDAQ:EPRX$7.42 -0.16 (-2.04%) As of 03:17 PM Eastern This is a fair market value price provided by Massive. Learn more.Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.Immix Biopharma NASDAQ:IMMX$9.73 -0.59 (-5.76%) As of 03:17 PM Eastern This is a fair market value price provided by Massive. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Kamada NASDAQ:KMDA$8.26 -0.02 (-0.24%) As of 03:15 PM Eastern This is a fair market value price provided by Massive. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Nuts and Bolts AI Play Gains Momentum: Astera Labs Targets Raised Anheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Light Speed Returns: Corning Cashes In on NVIDIA Growth Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
